Roche's cancer portfolio drives Q1 sales
This article was originally published in Scrip
Executive Summary
Growth of Roche's key brands Avastin (bevacizumab), MabThera/Rituxan (rituximab) and Herceptin (trastuzumab) spurred the group's first quarter with sales rising by 6% to CHF12.25 billion ($11.6 billion). Revenues were also aided by increased product demand and strong sales in emerging markets.